CN115103681A - 一种重组病毒载体、包含其的免疫组合物以及用途 - Google Patents

一种重组病毒载体、包含其的免疫组合物以及用途 Download PDF

Info

Publication number
CN115103681A
CN115103681A CN202080096622.2A CN202080096622A CN115103681A CN 115103681 A CN115103681 A CN 115103681A CN 202080096622 A CN202080096622 A CN 202080096622A CN 115103681 A CN115103681 A CN 115103681A
Authority
CN
China
Prior art keywords
tumor
human
viral vector
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080096622.2A
Other languages
English (en)
Other versions
CN115103681B (zh
Inventor
徐建青
黄杨
孙甲浩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vacdiagn Biotechnology Co ltd
Original Assignee
Vacdiagn Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vacdiagn Biotechnology Co ltd filed Critical Vacdiagn Biotechnology Co ltd
Publication of CN115103681A publication Critical patent/CN115103681A/zh
Application granted granted Critical
Publication of CN115103681B publication Critical patent/CN115103681B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

一种重组病毒载体、包含其的免疫组合物以及用途，所述重组病毒载体包含编码细胞因子的多核苷酸，所述细胞因子选自IL‑7、IL‑15、IL‑21或GM‑CSF中的一种或多种，该重组病毒载体可用于制备抗肿瘤疫苗。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN202080096622.2A 2020-02-18 2020-02-18 一种重组病毒载体、包含其的免疫组合物以及用途 Active CN115103681B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/075677 WO2021163874A1 (zh) 2020-02-18 2020-02-18 一种重组病毒载体、包含其的免疫组合物以及用途

Publications (2)

Publication Number Publication Date
CN115103681A true CN115103681A (zh) 2022-09-23
CN115103681B CN115103681B (zh) 2023-10-31

Family

ID=77391370

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080096622.2A Active CN115103681B (zh) 2020-02-18 2020-02-18 一种重组病毒载体、包含其的免疫组合物以及用途

Country Status (5)

Country Link
US (1) US20230270847A1 (zh)
EP (1) EP4108246A4 (zh)
JP (1) JP2023514337A (zh)
CN (1) CN115103681B (zh)
WO (1) WO2021163874A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116510022A (zh) * 2022-11-23 2023-08-01 武汉滨会生物科技股份有限公司 一种用于抗肿瘤的组合物、重组质粒组合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102575227A (zh) * 2008-10-08 2012-07-11 英特瑞克斯顿股份有限公司 表达多种免疫调节剂的工程改造细胞及其应用
CN103038343A (zh) * 2010-03-23 2013-04-10 英特瑞克斯顿股份有限公司 条件表达治疗蛋白的载体，包含所述载体的宿主细胞，及其应用
CN103110939A (zh) * 2012-10-23 2013-05-22 郑州大学 诱导肿瘤特异性免疫的疫苗及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003297155B2 (en) * 2002-12-16 2010-03-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant vaccine viruses expressing IL-15 and methods of using the same
EP3363907A1 (en) * 2004-05-27 2018-08-22 The Trustees of the University of Pennsylvania Novel artificial antigen presenting cells and uses therefor
KR20150038066A (ko) * 2012-07-30 2015-04-08 알렉스 와 힌 영 종양 세포, 암세포파괴 바이러스 벡터 및 면역 체크포인트 조절인자를 갖는 암 백신 시스템
GB201405834D0 (en) * 2014-04-01 2014-05-14 Univ London Queen Mary Oncolytic virus
RS62077B1 (sr) * 2016-05-30 2021-07-30 Astellas Pharma Inc Novi genetski modifikovan virus vakcinije
AU2017301880C1 (en) * 2016-07-29 2022-04-21 Juno Therapeutics, Inc. Immunomodulatory polypeptides and related compositions and methods
CN108686202A (zh) * 2017-04-06 2018-10-23 张晋宇 肿瘤免疫疗法
CN107354136A (zh) * 2017-06-15 2017-11-17 杭州睿可特生物科技有限公司 重组单纯疱疹病毒及其制备方法和应用
JP7277926B2 (ja) * 2017-11-08 2023-05-19 国立大学法人 鹿児島大学 安全を確保しながら転移性がんまで効果的に治療可能な、搭載する免疫誘導遺伝子の最適発現レベルを与える発現制御システムを有する腫瘍溶解性ウイルス（腫瘍溶解性免疫治療）
EP3831945A4 (en) * 2018-07-30 2022-05-04 Jinyu Zhang PROTEIN HETERODIMER AND ITS USE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102575227A (zh) * 2008-10-08 2012-07-11 英特瑞克斯顿股份有限公司 表达多种免疫调节剂的工程改造细胞及其应用
CN103038343A (zh) * 2010-03-23 2013-04-10 英特瑞克斯顿股份有限公司 条件表达治疗蛋白的载体，包含所述载体的宿主细胞，及其应用
CN103110939A (zh) * 2012-10-23 2013-05-22 郑州大学 诱导肿瘤特异性免疫的疫苗及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATRICK WILLIAMS 等: "A Fusion of GMCSF and IL-21 Initiates Hypersignaling Through the IL-21Rα Chain With Immune Activating and Tumoricidal Effects In Vivo" *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116510022A (zh) * 2022-11-23 2023-08-01 武汉滨会生物科技股份有限公司 一种用于抗肿瘤的组合物、重组质粒组合物及其应用
CN116510022B (zh) * 2022-11-23 2023-12-05 武汉滨会生物科技股份有限公司 一种用于抗肿瘤的组合物、重组质粒组合物及其应用

Also Published As

Publication number Publication date
CN115103681B (zh) 2023-10-31
US20230270847A1 (en) 2023-08-31
JP2023514337A (ja) 2023-04-05
EP4108246A4 (en) 2023-11-22
EP4108246A1 (en) 2022-12-28
WO2021163874A1 (zh) 2021-08-26

Similar Documents

Publication Publication Date Title
CN109554353B (zh) 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
US10093709B2 (en) GM-CSF and IL-4 conjugates, compositions, and methods related thereto
US9694059B2 (en) Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
US20220378887A1 (en) Tumor immunotherapy polypeptide and application thereof
CN114592010A (zh) NK-CAR-MbIL-15细胞及其制备方法和应用
Mikysková et al. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF
EA015510B1 (ru) Способ увеличения количества мононуклеарных клеток у субъекта, страдающего раком, и используемая для этого фармацевтическая комбинация
Moran et al. Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice
Yamanaka et al. Administration of interleukin-12 and-18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki Forest virus—mediated tumor complementary DNA
CN110214144B (zh) 多肽及其应用
CN101928695A (zh) 生产免疫细胞的方法及诱发产生免疫作用细胞的方法
Datta et al. Lysine: Is it worth more?
CN115103681A (zh) 一种重组病毒载体、包含其的免疫组合物以及用途
Paul et al. Improvement of adoptive cellular immunotherapy of human cancer using ex-vivo gene transfer
CN111849905B (zh) 间充质干细胞靶向运输趋化因子和细胞因子的免疫疗法
Wysocki et al. Genetically modified dendritic cells–a new, promising cancer treatment strategy?
EP4056197A1 (en) Tumor-specific polypeptide sequence and use thereof
CN110923266A (zh) 一种重组病毒载体、包含其的免疫组合物以及用途
CN111620955B (zh) 一种多靶位复合抗原及其应用
CN110139875B (zh) Col14a1衍生的肿瘤抗原多肽及其应用
RU2817896C1 (ru) Рекомбинантный вирус везикулярного стоматита, экспрессирующий химерный белок IL12-GMCSF
CN114702569B (zh) Pd-l1相关疫苗及其应用
WO2021087851A1 (zh) 一种重组病毒载体、包含其的免疫组合物以及用途
Cerullo et al. 538. Immunological Effects of Oral and Intravenous Cyclophosphamide in Cancer Patients Treated with Oncolytic Adenoviruses
CN115651913A (zh) 具有抗肿瘤活性的细胞及抑制肿瘤生长的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant